secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-051573
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q1 rev $211M, net loss narrows; secures $1.5B; launches BBOT
----------------------------------------------------------------------

- Revenue $211.1M vs $1.8M YoY; net loss $35.2M vs $140.2M prior year.
- Launched BBOT oncology subsidiary with $200M private financing led by Cormorant and Omega.
- Secured up to $1.5B via Bayer licensing (up to $310M milestones), royalty financing, and equity.
- Acoramidis NDA PDUFA date Nov 29, 2024; EMA MAA accepted, expected approval 2025.
- Ended Q1 with $519.8M cash; cash position strengthened significantly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/0000950170-24-051573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/bbio-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-051573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer